Castello De La Plana

• In vivo biological standardization of Dermatophagoides allergen extracts. Not authorised
  2024-514108-15-00 4 Allergies
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer Pending
  2025-520471-29-00 5 Locally advanced adenocarcinoma of the colon and upper rectum with mic
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf … Pending
  2025-521230-29-00 5 Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Der
• Prospective, randomized, multicentre study to compare the efficacy at 52 weeks (1 year) of biosimilar teriparatide and alendronate in the pr … Pending
  2025-521301-40-00 6 Prevention of new morphometric vertebral fractures and/or worsening of
• Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Pending
  2025-521709-42-00 5 Allergic rhinoconjunctivitis with or without asthma due to clinically
• Grass Immunotherapy for Rhinitis and Asthma (GIRA) Pending
  2025-521736-10-00 5 Allergic rhinoconjunctivitis with or without controlled asthma
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P … Pending
  2025-522471-28-00 5 psoriatic arthritis (PsA)
• A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending
  2025-525013-23-00 4 Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
• A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be … Recruiting
  2024-510778-26-00 4 2025-12-19 Metastatic Non-Small-Cell Lung Cancer
• Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tum … Recruiting
  2024-518131-11-02 4 2025-01-24 Localised Colon Cancer (stage II-III)
• A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec … Recruiting
  2024-512926-27-00 5 2024-12-12 patients with estrogen receptor-positive/human epidermal growth factor
• A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c … Recruiting
  2023-505606-42-00 5 2024-10-15 Head and Neck Squamous Cell Carcinoma (HNSCC)
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s … Recruiting
  2025-522979-29-00 5 2026-04-30 Acute myeloid leukemia
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy. A prosp … Recruiting
  2025-523119-12-00 10 2026-04-02 Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivit
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg … Recruiting
  2025-523083-21-00 5 2025-12-08 PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
• Dose determination study of a mix of Dermatophagoides allergenic extracts (pteronyssinus and farinae) for immunotherapy treatment, administe … Recruiting
  2025-521522-15-00 4 2025-11-05 Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy

Showing 1–24 of 99 trials